Recent Finacing
Recent Raise
ALX Oncology (Burlingame, CA) develops ALX148, a CD47-targeting checkpoint inhibitor evaluated as monotherapy and in combinations in Phase I trials for solid tumors and non-Hodgkin’s lymphoma.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at ALX Oncology.
